NAD+ Restoration Protocol: Boosting Cellular NAD+ Levels

Three strategies: (1) precursor supplementation (NMN 250–1,000 mg/day or NR 300–1,000 mg/day), (2) lifestyle (exercise increases NAMPT/NAD+ biosynthesis; time-restricted eating), (3) supporting sirtuin activity. Combining these is most effective.

NMN and NR are the leading precursors. Both elevate blood NAD+ in human trials. NR has more published human data and GRAS status; NMN has newer positive trials (Yoshino 2021). Neither is proven superior in a head-to-head trial.

Three main drivers: increased CD38 enzyme activity (primary NAD+ consumer), increased PARP consumption (DNA repair demand), and reduced NAMPT expression (rate-limiting biosynthesis enzyme). NAD+ drops ~50% between ages 40 and 60.

NAD+ is a coenzyme for energy metabolism (redox reactions in glycolysis, TCA cycle, electron transport) and a signaling molecule for sirtuins (epigenetic regulation, DNA repair) and PARPs (DNA repair). It's central to cellular energy and longevity signaling.

Common doses: 250–1,000 mg/day. Yoshino 2021 used 250 mg/day with positive insulin sensitivity results. Higher doses (up to 1,200 mg/day) have been studied safely. Follow product labels and consult your healthcare provider.

Yes. Multiple human trials confirm NMN elevates blood NAD+ levels with good tolerability. Yoshino 2021 showed 250 mg/day improved muscle insulin sensitivity in prediabetic women. Human outcome data beyond NAD+ elevation is still emerging.

Sirtuins (SIRT1-7) are NAD+-dependent enzymes that regulate epigenetics, DNA repair, mitochondrial function, and stress responses. NAD+ is their required co-substrate — declining NAD+ reduces sirtuin activity, linking energy status to aging.

Yes. Exercise increases NAMPT expression and NAD+ biosynthesis in muscle within 3–4 weeks. Time-restricted eating and caloric restriction also elevate NAD+. These lifestyle strategies complement but don't replace precursor supplementation for significant restoration.

NMN is one step closer to NAD+ in the salvage pathway. NR is converted to NMN inside cells by NRK1/2 enzymes. NR has GRAS status and more human trials; NMN's regulatory status varies. Both effectively raise NAD+.

Resveratrol activates SIRT1 (a NAD+-dependent sirtuin). Combining NMN/NR (raises NAD+) with resveratrol (activates sirtuins) may enhance sirtuin activity beyond either alone, though this combination has limited direct clinical trial data.

Morning dosing is commonly recommended (aligns with circadian NAD+ rhythms, which peak in the morning). Some split doses morning and afternoon. Avoid evening dosing as it may affect sleep. Follow product guidance.

No serious adverse events reported in trials up to 1,200 mg/day. Mild effects may include flushing, GI upset, or headache. NMN has excellent safety characterization in published human studies.

Blood NAD+ (whole blood or serum) is measurable but reflects only ~1% of body NAD+. RBC NAD+ is more stable. Research uses tissue biopsies. Practical clinical monitoring is limited — most supplement based on symptoms and evidence.

NAD+ restoration shows promise in age-related decline (cardiovascular, metabolic). Martens 2018 showed NR improved blood pressure/aortic stiffness in older adults. Human longevity outcome data is still emerging — not proven to extend human lifespan.

Blood NAD+ elevation occurs within days to weeks of precursor supplementation. Functional outcomes (insulin sensitivity, cardiovascular markers) appear over weeks to months. Lifestyle effects compound over months. This is a sustained strategy.